Aurion Biotech announced that the first participant has been dosed in its phase 1/2 trial of AURN001, an investigational cell therapy for treatment of corneal edema secondary to corneal endothelial dysfunction.
According to a company press release, AURN001 is a combination of neltependocel — allogenic human corneal endothelial cells — and Y-27632, a Rho kinase inhibitor.
“On the heels of our recent approval in Japan, we are very pleased to have begun dosing subjects in this trial in the United States,” Michael Goldstein, MD, MBA, Aurion’s president and chief